Arca
Skip to content

Sesquient (fosphenytoin sodium): Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See NDA 210864's history or Sedor Pharmaceuticals's company page.

On Mar 22, 2019, FDA declined to approve Sesquient (fosphenytoin sodium) (NDA 210864) from Sedor Pharmaceuticals, LLC in its present form. The application was later approved.

  • Letter date: Mar 22, 2019
  • Application: NDA 210864
  • Since then: Approved

The Letter

Text from openFDA

We have described our reasons for this action below and, where possible, our recommendations to address these issues. Product Quality 1. The proposed prescribing information indicates that the drug product can be diluted in either 5% dextrose or 0.9% saline to...… openFDA did not return the full text just now. Open it in the letter search.

Other Letters on This Application

Record

Company
Sedor Pharmaceuticals, LLC
Application
NDA 210864
Status in openFDA
Approved
Review division
Division of Neurology Products

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.